NCT02954692View on ClinicalTrials.gov

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

PHASE4CompletedINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 22, 2017

Study Completion Date

December 22, 2017

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

INSULIN GLARGINE (U300)

"Pharmaceutical form: pen for injection~Route of administration: subcutaneous"

DRUG

metformin

"Pharmaceutical form: tablet~Route of administration: oral"

DRUG

sulfonylurea

"Pharmaceutical form: tablet~Route of administration: oral"

DRUG

meglitinides

"Pharmaceutical form: tablet~Route of administration: oral"

DRUG

thiazolidinediones

"Pharmaceutical form: tablet~Route of administration: oral"

DRUG

alpha-glucosidase inhibitors

"Pharmaceutical form: tablet~Route of administration: oral"

DRUG

GLP1 Receptor Agonist

"Pharmaceutical form: pen for injection~Route of administration: subcutaneous"

DRUG

Dipeptidyl peptidase-IV (DPP-IV) inhibitors

"Pharmaceutical form: tablet~Route of administration: oral"

DRUG

Sodium-glucose transport-2 (SGLT-2) inhibitors

"Pharmaceutical form: tablet~Route of administration: oral"

Trial Locations (1)

Unknown

Turkey

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY